as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: National Institute of Allergy and Infectious Diseases Special Emphasis Panel; NIAID New Innovators Awards (DP2 Clinical Trial Not Allowed).

Date: March 11–13, 2024.

Time: 10:00 a.m. to 6:00 p.m.

Agenda: To review and evaluate grant applications.

Place: National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, Rockville, MD 20852 (Video Assisted Meeting).

Contact Person: Vanitha Sundaresa Raman, Scientific Review Officer, Scientific Review Program, Division of Extramural Activities, National Institute of Allergy and Infectious Diseases, National Institutes of Health, 5601 Fishers Lane, MSC 9834, Rockville, MD 20852, 301–761–7949, *vanitha.raman@nih.gov*.

(Catalogue of Federal Domestic Assistance Program Nos. 93.855, Allergy, Immunology, and Transplantation Research; 93.856, Microbiology and Infectious Diseases Research, National Institutes of Health, HHS)

Dated: February 12, 2024.

Lauren A. Fleck,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–03195 Filed 2–14–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852 by contacting Dawn Taylor-Mulneix at 301–451–8021 or *dawn.taylor-mulneix@nih.gov.* A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

Equipping Natural Killer Cells With a CD28H-Containing Chimeric Antigen Receptor To Overcome Inhibition for Cancer Immunotherapy

Description of Technology

Immunotherapy with chimeric antigen receptor (CAR) cytotoxic T cells have been successful in the clinical treatment of hematologic cancers; however adverse side effects such as severe cytokine release syndrome and neurotoxicity are associated with CAR–T cell infusion. CAR natural killer (NK) cells represent a viable alternative with demonstrated advantages over CAR–T cells for the elimination of tumor cells, but NK inhibitory cell receptors need to be reduced or overridden. To overcome this challenge, scientists at NIAID have developed CAR constructs that overcome inhibition of NK cells by receptors for human major histocompatibility complex molecules HLA–E and HLA–C, based on in vitro studies. NK cells that are expressing variants of this invention robustly overcome inhibition imposed by $CD19^+$ $HLA–I^+$ tumor cells and are cytotoxic to them.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404, as well as for further development and evaluation under a research collaboration.

Potential Commercial Applications

- Method of adoptive cell therapy where CAR–NK cells are the effective cell.

Competitive Advantages

- CD28H CAR–NK cells induce a more robust anti-tumor cytotoxic activity compared to third generation CAR–T cells and are more potent in overcoming inhibition.
- CAR–NK can be developed without the need of genetic silencing of TCR.

Developmental Stage

- Pre-clinical.

Inventors: Eric Long, Ph.D. and Xiaoxuan Zhuang, both of NIAID.

Publications:

Zhuang X., Long E.O., ''NK cells equipped with a chimeric antigen receptor that overcomes inhibition by HLA Class I for adoptive transfer of CAR–NK Cells. Front. Immunol. 13:840844. *https://www.frontiersin.org/articles/10.3389/fimmu.2022.840844/full.* May 2, 2022.

Zhuang X. and Long E.O., ''CD28 homolog is a strong activator of Natural Killer cells for lysis of B7H7-positive tumor cells.'' Cancer Immunol. Res. 7(6):939–951. *https://cancerimmunolres.aacrjournals.org/content/7/6/939.long.* April 24, 2019.

Zhuang X, Long E.O. ''Inhibition-resistant CARs for NK cell cancer immunotherapy.'' Trends Immunol. 40(12):1078–1081.*https://www.sciencedirect.com/science/article/pii/S1471490619302133?via%3Dihub.* November 12, 2019.

Intellectual Property: HHS Reference No. E–097–2020; Patent Application Nos.: PCT Application No. PCT/US2020/02498, US: 17/914,027, Australia: 2020437669, Brazil: BR112022017512–4, Canada: 3174779, Europe: 20719313.7, India: 2022170585054, Japan: 2022–557764, South Korea: 10–2022–7037236.

Licensing Contact: To license this technology, please contact Dawn Taylor-Mulneix at 301–451–8021 or *dawn.taylor-mulneix@nih.gov,* and reference E–097–2020.

Collaborative Research Opportunity: The National Institute of Allergy and Infectious Diseases is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. For collaboration opportunities, please contact Dawn Taylor-Mulneix at 301–451–8021 or *dawn.taylor-mulneix@nih.gov.*

Dated: February 9, 2024.

Surekha Vathyam,

Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.

[FR Doc. 2024–03121 Filed 2–14–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Charter Renewal

In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the charter for the Cures Acceleration Network Review Board, was renewed for an additional two-year period on February 7, 2024.

It is determined that the Cures Acceleration Network Review Board, is in the public interest in connection with the performance of duties imposed on the National Institutes of Health by law, and that these duties can best be performed through the advice and counsel of this group.

Inquiries may be directed to Claire Harris, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496–2123, or *harriscl@mail.nih.gov.*

Dated: February 9, 2024.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–03110 Filed 2–14–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Office of the Director; Notice of Charter Renewal

In accordance with Title 41 of the U.S. Code of Federal Regulations, Section 102–3.65(a), notice is hereby given that the charter for the National Center for Advancing Translational Sciences Advisory Council, was renewed for an additional two-year period on February 7, 2024.

It is determined that the National Center for Advancing Translational Sciences Advisory Council, is in the public interest in connection with the performance of duties imposed on the National Institutes of Health by law, and that these duties can best be performed through the advice and counsel of this group.

Inquiries may be directed to Claire Harris, Director, Office of Federal Advisory Committee Policy, Office of the Director, National Institutes of Health, 6701 Democracy Boulevard, Suite 1000, Bethesda, Maryland 20892 (Mail code 4875), Telephone (301) 496–2123, or *harriscl@mail.nih.gov.*

Dated: February 9, 2024.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024–03104 Filed 2–14–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The invention listed below is owned by an agency of the U.S. Government and is available for licensing to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT: Daniel Lee at 301–761–6327 or *daniel.lee5@nih.gov.* Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301–496–2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.

SUPPLEMENTARY INFORMATION: Technology description follows:

DeePlexing—Extending Imaging Multiplexity Using Machine Learning

Description of Technology: Spatial proteomics and transcriptomics are fast-emerging fields with the potential to revolutionize various branches of biology. In the last five years, various multiplex immunofluorescence and immunohistochemistry imaging methods have been developed to stain 5–60 different protein markers in a given tissue. Nonetheless, most of these techniques are iterative and can image a maximum of 3–8 markers in a single cycle, resulting in processing time of several hours to days.

Scientists at National Institute of Allergy and Infectious Diseases (NIAID) and National Cancer Institute (NCI) have developed a new method—DeePlexing—that uses a deep learning algorithm to dramatically enhance the number of markers stained in a single imaging cycle. This is accomplished with no changes or upgrades to the imaging platform itself. In the DeePlexing method, multiple antibodies/probes are conjugated to the same fluorophores and later deconvolved computationally to retrieve the multichannel signal with high accuracy. In digital spatial profiling, DeePlexing enables the user to detect seven different protein markers in a single cycle using only three fluorophores and even quadruple the number of markers in a single round without compromising the quality of RNA and protein in the sample. For multiplex protein profiling, DeePlexing can potentially stain for up to 255 different protein markets with eight fluorophores and deconvolve the signal for each of the 255 markers computationally.

This technology is available for licensing for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.

Potential Commercial Applications:

- Imaging platforms in spatial transcriptomics
- Multiplex protein spatial imaging

Competitive Advantages:

- Enhances the number of markers stained in a single imaging cycle
- Achieves this marker detection increase without compromising RNA or protein quality when that is part of the analytical pipeline
- Reduces the required processing time for multiplex imaging platforms
- Inexpensive and replicable

Development Stage:

- Prototype

Inventors: Ronald N. Germain (NIAID), Spencer M. Grant (NIAID), Nishant Thakur (NIAID), Chen Zhao (NCI), and Abigail J. Wong-Rolle (NCI).

Intellectual Property: HHS Reference No. E–202–2021–0; Software Tool.

Licensing Contact: To license this technology, please contact Daniel Lee at 301–761–6327 or *daniel.lee5@nih.gov,* and reference E–202–2021–0.

Dated: February 9, 2024.

Surekha Vathyam,

Deputy Director,Technology Transfer and Intellectual Property Office,National Institute of Allergy and Infectious Diseases.

[FR Doc. 2024–03120 Filed 2–14–24; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Substance Abuse and Mental Health Services Administration

Notice of Meeting for the Interdepartmental Serious Mental Illness Coordinating Committee (ISMICC)

AGENCY: Substance Abuse and Mental Health Services Administration, Department of Health and Human Services.